MedTrace Logo

Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis

NCT02837146 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2016-07-29

No results posted yet for this study

Summary

This study is aimed at assessing the kinetics of the ultrasound (US) response in DMARD-naive very early rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and methotrexate (MTX).

Conditions

Interventions

BIOLOGICAL

Tocilizumab (TCZ)

Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24

DRUG

Methotrexate (MTX)

Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54

Sponsors & Collaborators

  • Maria Stoenoiu

    lead OTHER

Principal Investigators

  • Maria S Stoenoiu, MD, PhD · Université Catholique de Louvain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2018-12-31
Completion
2019-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02837146 on ClinicalTrials.gov